Last year the labs of Mark Zylka and Ben Philpot at the University of North Carolina at Chapel Hill discovered that a class of drugs
called topoisomerase inhibitors reduces the expression of long genes.
Although this class of compounds has shown efficacy in a variety of cancers, interest in developing
new topoisomerase I inhibitors, indenoisoquinolines, are currently being evaluated in human patients as agents with improved drug stability and measurable blood levels.
Phase I Clinical Trial of VX - 970 in Combination with
the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors
A class of anticancer compounds, called
topoisomerase inhibitors, is shown by Cancer Center scientists to initiate antitumor responses in treatment - resistant cancers.
Also, a 2012 study published on the Medical Journal 3 Biotech shows that the anti-cancer compounds in mushrooms play a crucial role as a reactive oxygen species inducer, mitotic kinase inhibitor, antimitotic, angiogenesis inhibitor,
topoisomerase inhibitor all leading to apoptosis (cell death) and eventually checking cancer cell proliferation (4).